Eli Lilly and Company (NYSE:LLY) Holdings Decreased by Quotient Wealth Partners LLC

Quotient Wealth Partners LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 3.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,009 shares of the company’s stock after selling 104 shares during the quarter. Quotient Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $2,665,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company in the second quarter worth about $32,000. LGT Financial Advisors LLC bought a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $36,000. Redmont Wealth Advisors LLC bought a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $40,000. Morton Brown Family Wealth LLC raised its holdings in Eli Lilly and Company by 45.5% during the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after purchasing an additional 15 shares in the last quarter. Finally, Richardson Financial Services Inc. bought a new position in Eli Lilly and Company during the 4th quarter valued at $43,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.6 %

NYSE:LLY traded down $5.69 on Thursday, hitting $914.05. 608,248 shares of the stock were exchanged, compared to its average volume of 3,007,731. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The stock has a market capitalization of $868.72 billion, a price-to-earnings ratio of 134.49, a P/E/G ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company’s 50-day moving average price is $906.72 and its 200 day moving average price is $850.80.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. On average, equities research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Barclays raised their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Citigroup assumed coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price objective for the company. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $979.29.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.